The study evaluates the utility of aprepitant in managing pediatric Cyclic Vomiting Syndrome (CVS) using data from the Pediatric Health Information System (PHIS). Despite longer hospital stays and higher costs in the aprepitant group, no significant reduction in 7-day readmission rates was observed. Clarification is needed on why clinical severity indices (e.g., vomiting frequency) were not included in propensity score matching, as these could provide a more accurate assessment of aprepitant’s effectiveness. A visual representation of readmission trends and more detail on how differences from prior studies (e.g., adult populations) were contextualized would enhance understanding. Could the authors elaborate on these points?
